Open AccessThe efficacy of fluoropyrimidine‐based adjuvant chemotherapy on biliary tract cancer after R0 resection
Author(s) -
Kim Young Saing,
Jeong ChiYoung,
Song HaaNa,
Kim Tae Hyo,
Kim Hong Jun,
Lee YoungJoon,
Hong Soon Chan
Publication year - 2017
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.1186/s40880-017-0182-y
Subject(s) - biliary tract cancer , medicine , chemotherapy , adjuvant , biliary tract , adjuvant chemotherapy , resection , cancer , oncology , gemcitabine , surgery , breast cancer
Background The optimal treatment strategy for biliary tract cancer (BTC) after curative‐intent resection remains controversial. The purpose of this study was to evaluate the efficacy of fluoropyrimidine‐based adjuvant chemotherapy for BTC patients undergoing microscopically margin‐negative (R0) resection. Methods We retrospectively analyzed the clinical data of BTC patients who underwent curative‐intent R0 resection. Patients were eligible if they received either fluoropyrimidine‐based adjuvant chemotherapy or observation after R0 resection. Results A total of 153 patients were included. In the entire patient cohort, no significant differences were observed in 5‐year overall survival (OS) rates (48.4% vs. 39.6%, P = 0.439) or 3‐year recurrence‐free survival (RFS) rates (49.1% vs. 39.5%, P = 0.299) between patients who received fluoropyrimidine‐based adjuvant chemotherapy or observation. However, for patients with stages II and III BTC, chemotherapy significantly improved 5‐year OS rate (52.4% vs. 35.6%, P = 0.002) and 3‐year RFS rate (55.5% vs. 39.1%, P = 0.021) compared with observation. Conclusion Fluoropyrimidine‐based adjuvant chemotherapy may prolong the survival of patients with stages II and III BTC after R0 resection.